Categories: AssistedBioTechBusinessEconomyInvestmentResearch
Amporin Pharma is developing a breakthrough new class of membrane-protecting therapies that could transform the treatment of degenerative diseases associated with protein misfolding and aggregation, including Alzheimer's, Parkinson's, diabetes, and at least 50 rare degenerative diseases. Together, these diseases affect over half a billion people and cost the global economy USD 3 trillion per year, yet still there are no effective treatments. Amporin's founders include Dr Kelvin Stott as CEO, with over 20 years of R&D leadership experience in Big Pharma, biotech, business consulting and venture capital, and Dr Jinghui Luo, Research Group Leader at the Paul Scherrer Institute.
Investors 1
Mentions in press and media 2
Reviews 0
